AI Article Synopsis
- The study aimed to describe choroidal amyloid angiopathy (CAA) using late-phase indocyanine green angiography (ICGA) in patients with transthyretin (ATTR) and AL amyloidosis.
- A total of 32 patients were evaluated; hyperfluorescent spots indicating CAA were found in 89% of the eyes, with a median time to peak staining of 672 seconds, significantly longer than initial staining.
- Most patients showed improvement in CAA during treatment, suggesting it may reflect systemic disease status, although some developed complications like vitreous opacities and glaucoma.
Article Abstract
Purpose: To characterize choroidal amyloid angiopathy (CAA) using late-phase indocyanine green angiography (ICGA).
Methods: This was a multicenter retrospective observational case series on patients with transthyretin (ATTR) and AL amyloidosis who underwent ICGA. The timing of hyperfluorescence and longitudinal changes were analyzed.
Results: Thirty-two patients (27 with ATTR and 5 with AL) with mean age of 58.9 ± 17.4 years were included. Hyperfluorescent spots in the very late phases of ICGA, corresponding to CAA, were observed in 49 of 55 eyes (89%). The median time to maximal staining was 672 (95% confidence interval, 644-752) seconds, which was significantly later than the initial staining (503 [95% confidence interval, 447-521], P < 0.0001; Wilcoxon signed rank test). In seven patients with ATTR amyloidosis who underwent follow-up of ICGA, the CAA was stable in two patients and improved in five patients during treatment. However, 3 patients (43%) had worsening vitreous opacities in both eyes, and 4 patients (57%) developed secondary open-angle glaucoma.
Conclusion: Most patients with amyloidosis were found to have CAA on ICGA. Up to 12.5 minutes is required for maximal ICG staining. Choroidal amyloid angiopathy improved in most patients with systemic treatment and may serve as a marker of systemic disease status.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/IAE.0000000000003551 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Brain macrophages in vascular health and dysfunction.
Trends Immunol
January 2025
Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland. Electronic address:
Diverse macrophage populations inhabit the rodent and human central nervous system (CNS), including microglia in the parenchyma and border-associated macrophages (BAMs) in the meninges, choroid plexus, and perivascular spaces. These innate immune phagocytes are essential in brain development and maintaining homeostasis, but they also play diverse roles in neurological diseases. In this review, we highlight the emerging roles of CNS macrophages in regulating vascular function in health and disease.
View Article and Find Full Text PDFTransmembrane protein 106B amyloid is a potential off-target molecule of tau PET tracers in the choroid plexus.
Nucl Med Biol
December 2024
Research Center for Accelerator and Radioisotope Science (RARiS), Tohoku University, Sendai, Japan; Graduate School of Pharmaceutical Science, Tohoku University, Sendai, Japan. Electronic address:
Purpose: Tau positron emission tomography (PET) has become an essential tool for the clinical diagnosis of neurodegenerative diseases and the study of tau pathology in the brain. However, some tau tracers exhibit off-target binding in the basal ganglia, choroid plexus, and meninges. Recently, transmembrane protein 106B (TMEM106B) was identified to form novel amyloid filaments in the brain during aging.
View Article and Find Full Text PDFNon-invasive MRI of blood-cerebrospinal fluid-barrier function in a mouse model of Alzheimer's disease: a potential biomarker of early pathology.
Fluids Barriers CNS
December 2024
Champalimaud Research, Champalimaud Foundation, Av. Brasilia, Lisbon, 1400-038, Portugal.
Article Synopsis
- The choroid plexus (CP) and blood-cerebrospinal fluid-barrier (BCSFB) play a critical role in producing and clearing cerebrospinal fluid, and their dysfunction is linked to neurodegenerative diseases like Alzheimer's disease (AD).
- This study utilized advanced MRI techniques to measure water delivery across the BCSFB in a triple transgenic mouse model of AD, observing significant changes in CP function even before clinical symptoms appear.
- Results indicated increased BCSFB-mediated water delivery in younger mice, with notable behavioral differences arising around 20 weeks, suggesting that CP changes could serve as early biomarkers for AD.
Pathogenesis, manifestations, diagnosis, and management of CNS complications in hereditary ATTR amyloidosis.
Amyloid
December 2024
Unidade Corino de Andrade, Centro Hospitalar Universitário de Santo António, Porto, Portugal.
The clinical efficacy of transthyretin (TTR) tetramer stabilisers and gene silencers in addition to liver transplantation has been established for hereditary ATTR (ATTRv) amyloidosis. Accordingly, non-central nervous system (CNS) systemic amyloidosis manifestations, such as peripheral neuropathy and cardiomyopathy, are now being overcome. However, emerging disease-modifying therapeutics have limited effects on CNS amyloidosis since they target the blood-circulating TTR produced in the liver, and not the cerebral spinal fluid (CSF) TTR synthesised in the choroid plexus.
View Article and Find Full Text PDFApplying low levels of strain to model nascent phenomenon of retinal pathologies.
Lab Chip
December 2024
Biological Engineering, Utah State University College of Engineering, 4105 Old Main Hill, ENGR 402, Logan, Utah, USA.
Age-related macular degeneration (AMD) is a leading cause of vision loss in aging populations. A better understanding of the mechanisms of the disease, especially at early stages, could elucidate new treatment targets. One characteristic of AMD is strain on the retinal pigment epithelium (RPE), a crucial layer of the retina.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!